---
schema_version: "secwatch.filing_event.v1"
accession: "0001562762-23-000046"
form_type: "8-K"
ticker: "GMED"
cik: "0001237831"
company_name: "GLOBUS MEDICAL INC"
filed_at: "2023-02-21T23:59:59+00:00"
generated_at: "2026-06-19T06:30:39.516424+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Globus Medical Q4 net sales $274.5M (+9.8% YoY); full year exceeds $1B; guides 2023 sales $1.1B

## Summary
- Q4 GAAP diluted EPS $0.49, non-GAAP diluted EPS $0.59; net income $50.1M (+231% YoY).
- Full year 2022 net sales $1,022.8M (+6.8% YoY); GAAP diluted EPS $1.85, non-GAAP $2.06.
- Non-GAAP adjusted EBITDA Q4 $90.2M (32.8% of sales); full year $339.2M (33.2%).
- 2023 guidance: net sales ~$1.1B, non-GAAP diluted EPS $2.30.
- Company remains debt-free; net cash from ops $178.5M, free cash flow $104.4M for full year.

## SEC filing metadata
- accession: 0001562762-23-000046
- form_type: 8-K
- ticker: GMED
- cik: 0001237831
- company_name: GLOBUS MEDICAL INC
- filed_at: 2023-02-21T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1237831/000156276223000046/0001562762-23-000046-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1237831/000156276223000046/gmed-20230221x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001562762-23-000046
- JSON: https://secwatch.observer/filing/0001562762-23-000046.json
- Plain text: https://secwatch.observer/filing/0001562762-23-000046.txt

## Key facts
- Earnings Releases
  GLOBUS MEDICAL INC reported Full Year 2022 results: revenue $1,022.8 million, net income $190.2 million, EPS $1.85.
  - Period: Full Year 2022
  - Revenue: $1,022.8 million
  - Net income: $190.2 million
  - EPS: $1.85
  - Result: reported results
  source text: Full Year 20 2 2 : · Worldwide net sales were $ 1,022.8 million , an increase of 6.8 % , or 8.2% on a constant currency basis · GAAP n et income for the year was $ 1 90.2 million · GAAP d iluted EPS was $ 1. 85 and n on-GAAP diluted EPS was $ 2.0 6 · Non-GAAP adjusted EBITDA was $ 33 9.2 million, or 3 3.2 % of net sales
  evidence_url: https://www.sec.gov/Archives/edgar/data/1237831/000156276223000046/0001562762-23-000046-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.